Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Clinical trial NCT06478472 · RECRUITING
Trial details
- NCT number
- NCT06478472
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-23
- Primary completion
- 2027-06-23
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.